Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sepracor To Increase Lunesta Promotional Spend After Pfizer Drops Indiplon

This article was originally published in The Pink Sheet Daily

Executive Summary

Sepracor plans to increase DTC, professional marketing programs to make up for the absence of Pfizer's initiatives to grow the sleep aid market.

You may also be interested in...



Sepracor Sees Sweet Dreams For Lunesta Despite Generic Ambien Next Year

Firm says formulary placement of the sleep aid will help mitigate Rx erosion following the launch of generic Ambien.

Sepracor Sees Sweet Dreams For Lunesta Despite Generic Ambien Next Year

Firm says formulary placement of the sleep aid will help mitigate Rx erosion following the launch of generic Ambien.

Rozerem DTC Ads Highlight Low Abuse Potential Of Sleep Aid

Takeda launches Rozerem TV spots promoting sweet dreams with a humorous approach.

Related Content

Topics

UsernamePublicRestriction

Register

OM006145

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel